ClinicalTrials.gg

Program

HLX97

A development code.

In Fosun Pharma's pipeline, KAT6A/B. Its studies are led by Fosun Pharma.

Furthest: phase 1, since Mar 13, 20261 company-led study, 1 open or runningNext primary completion: Mar 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Mar 13, 2026Mar 13, 2026Mar 2028phase 1 · NCT07480681
  • Named in Fosun Pharma’s own pipeline as HLX97 (KAT6A/B), phase 1, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2026First study: phase 1 study in Advanced/Metastatic Solid TumorsFirst studyNCT07480681 · 138 planned

Ahead

  1. Mar 2028Primary completion: phase 1 study in Advanced/Metastatic Solid TumorsNCT07480681

TargetBeta

“KAT6A/B”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
prifetrastatPfizerphase 310
KAT6A/B Inhibitor BG-75202ruleBeOne Medicinesphase 12
HRS-2189Jiangsu HengRui Medicinephase 12
KAT6 Inhibitor OP-3136ruleolema-pharmaceuticals-incphase 11
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 11
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07480681Advanced/Metastatic Solid Tumors1Not yet recruitingMar 2028138

How it is read

Names in the registry

  • “HLX97”, 1 entry

Codes read as this program: HLX97.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.